Retatrutide (GLP-3R) | Pen

GLP-3R is an investigational multi-receptor agonist designed to engage three metabolic hormone pathways: GLP-1R, GIPR, and GCGR. By combining incretin-driven appetite and glucose signaling with glucagon-linked energy expenditure pathways, it is positioned for controlled research settings focused on body-weight dynamics, glycemic regulation, and lipid-metabolism endpoints.

Supports

1. Appetite and satiety signaling context associated with incretin receptor activity.
2. Glycemic balance frameworks linked to glucose-dependent insulin and glucagon dynamics.
3. Energy expenditure signaling context associated with glucagon-pathway activation in models.
4. Lipid oxidation and fat-mobilization frameworks tracked in metabolic research endpoints.
5. Hepatic lipid-handling context relevant to steatosis-related research readouts.

Description

GLP-3R is a synthetic unimolecular agonist engineered to activate GLP-1, GIP, and glucagon receptors within a single compound. This tri-agonist architecture is widely studied as a next-generation approach to whole-body metabolic remodeling because it targets complementary nodes of energy intake, glucose handling, and fuel utilization. In experimental settings, the combination is used to examine coordinated changes across appetite control, glycemic parameters, and lipid-flux endpoints.

GLP-1R and GIPR activation are commonly explored for their roles in postprandial signaling and glucose-dependent insulin effects, while GCGR activation is frequently studied in relation to thermogenic signaling and hepatic fatty acid oxidation. As a combined profile, GLP-3R is positioned for research protocols that track weight, metabolic biomarkers, and liver-fat readouts under controlled conditions.

This product is presented for research and educational context only. It is not marketed as an approved therapeutic product, and reported outcomes can vary substantially by study design, model, and protocol parameters.

Clinical Status

GLP-3R is an investigational compound with published human and preclinical research describing metabolic endpoints across obesity and metabolic-disease study contexts. Regulatory approvals for therapeutic use are not presented here, and interpretation of results should remain study-specific and endpoint-driven.

Evidence type:
Human RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

As a multi-receptor agonist, GLP-3R engages GLP-1R, GIPR, and GCGR to trigger cAMP-mediated signaling cascades that influence appetite regulation, glucose-dependent pancreatic signaling, and hepatic lipid metabolism. In model systems, incretin receptor activity is often linked to delayed gastric emptying and satiety signaling, while glucagon receptor activity is frequently associated with increased energy expenditure, thermogenic pathways, and enhanced fatty acid oxidation.

Preclinical data commonly frame the tri-agonist profile around shifts in AMPK-related metabolic signaling and downstream effects on lipid handling and inflammatory-marker patterns. The relative contribution of each receptor pathway can differ by model, dosing window, and endpoints selected.

Benefits

• Triple Agonist Mechanism for Comprehensive Metabolic Regulation:
  Rеtаtrutіdе is a potent GLP-1, GIP, and glucagon receptor agonist, studied for its multi-pathway activation of energy metabolism. By engaging all three receptors, it enhances insulin secretion, suppresses appetite, and promotes lipid oxidation simultaneously. This triple agonist design provides broader metabolic modulation than single or dual incretin analogs, making it a leading subject in next-generation obesity and diabetes research.
• Exceptional Weight Reduction Outcomes:
  Clinical and preclinical data show that Rеtаtrutіdе can produce up to 24% body weight reduction over extended treatment periods. This outcome surpasses previous GLP-1 or GLP-1/GIP agonists due to enhanced thermogenesis and fat oxidation mechanisms. Research indicates a sustained and progressive decline in both subcutaneous and visceral fat mass, positioning Rеtаtrutіdе as a new benchmark in metabolic optimization studies.
• Marked Reduction in Visceral and Hepatic Fat:
  Rеtаtrutіdе has been observed to dramatically reduce liver fat content (over 80% in clinical data) and visceral adiposity in both obese and type 2 diabetic subjects. This effect stems from its ability to activate glucagon receptor-mediated lipid metabolism and enhance mitochondrial β-oxidation, promoting improved liver function and systemic metabolic balance.
• Improvement in Glucose Control and Insulin Sensitivity:
  Through simultaneous activation of incretin pathways, Rеtаtrutіdе enhances insulin secretion, suppresses glucagon, and improves peripheral glucose uptake. This coordinated metabolic effect results in significant HbA1c reduction and stabilization of fasting glucose levels in research subjects. These findings highlight its potential as one of the most effective glucose-lowering peptides under investigation.
• Enhanced Lipid Profile and Cardiovascular Markers:
  Rеtаtrutіdе administration has been associated with improved lipid metabolism, including reductions in total cholesterol, LDL, and triglycerides. Studies also report lower systolic blood pressure and inflammatory markers such as CRP, suggesting favorable cardiometabolic outcomes in long-term metabolic studies.
• Stimulation of Energy Expenditure and Thermogenesis:
  In animal models, Rеtаtrutіdе increases thermogenic activity in brown adipose tissue via glucagon receptor signaling, leading to higher resting energy expenditure. Enhanced mitochondrial respiration and fatty acid oxidation contribute to continuous fat loss even under moderate caloric intake, establishing its potential as a metabolic rate enhancer in research applications.
• Reduction of Systemic Inflammation:
  Rеtаtrutіdе has been observed to reduce inflammatory cytokines such as TNF-α and IL-6, while improving endothelial function and vascular elasticity. These anti-inflammatory and vasoprotective effects complement its metabolic actions, promoting improved cardiovascular resilience in experimental models of metabolic disease.
• Preservation of Lean Body Mass:
  Research findings suggest that despite substantial fat loss, Rеtаtrutіdе supports the maintenance of lean muscle tissue. This balance between adipose reduction and muscle preservation reflects its unique energy-partitioning effect, making it valuable for studies exploring body recomposition and athletic performance enhancement.
• Liver Function and NAFLD Improvement:
  Preclinical and early clinical studies show significant improvements in non-alcoholic fatty liver disease (NAFLD) parameters, including reduced hepatic inflammation and fibrosis. Rеtаtrutіdе’s triple-agonist activation enhances AMPK signaling, reducing lipid accumulation and promoting hepatic regeneration in metabolic liver research.
• Synergistic Effects with GLP-1 and Mitochondrial Peptides:
  Experimental protocols combining Rеtаtrutіdе with Sеmаglutіdе, MOTS-c, or SS-31 are being explored to enhance mitochondrial bioenergetics, lipid metabolism, and overall metabolic performance. These stacked combinations aim to maximize fat oxidation, reduce inflammation, and sustain high energy efficiency in long-term research models.
• Long-Term Metabolic Adaptation and Weight Maintenance:
  Follow-up studies indicate that subjects maintained over 80% of their weight loss after extended observation periods, even after discontinuation. This sustained adaptation reflects durable improvements in metabolic set-point, appetite control, and mitochondrial efficiency, marking Rеtаtrutіdе as a highly promising agent for advanced metabolic research.

Research Data

Stack Suggestions

In extended experimental designs, GLP-3R is sometimes paired with:

• Rеtаtrutіdе + Cagrilintide – appetite control plus energy-expenditure focus for body-weight endpoints.
  Rationale: Amylin-analog synergy on satiety with triple-agonist metabolic activation.
• Rеtаtrutіdе + 5-Amino-1MQ – lipid-flux modulation with NNMT inhibition alongside incretin-glucagon signaling.
  Rationale: Encourages fat-use preference while reducing lipogenesis signals.
• Rеtаtrutіdе + NAD+ – cellular-energy and mitochondrial-support cofactor during rapid metabolic shifts.
  Rationale: Supports redox balance in intensive weight-loss paradigms.
• Rеtаtrutіdе + BPC-157/TB-500 (recovery contexts) – tissue comfort and adherence during lifestyle interventions.
  Rationale: Soft-tissue support may reduce musculoskeletal barriers to activity.
  

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Scientific References

• Triple-hormone-receptor agonist rеtаtrutіdе for obesity Human RCT
• Efficacy and safety of rеtаtrutіdе, a novel GLP-1, GIP, and glucagon receptor agonist, in adults with obesity: a randomised, placebo-controlled, phase 2 trial Human RCT
• Rеtаtrutіdе – a game changer in obesity pharmacotherapy Observational
• Unleashing the power of rеtаtrutіdе: a possible triumph over obesity and its comorbidities Animal
• Effects of once-weekly subcutaneous Rrеtаtrutіdе on weight and metabolic markers in adults with obesity: a randomized phase 2 trial Human RCT
• Effects of rеtаtrutіdе on body composition in people with type 2 diabetes: a post hoc analysis of a randomised, double-blind, placebo-controlled phase 2 trial Human RCT
• A review of an investigational drug Rеtаtrutіdе, a novel triple agonist agent for the treatment of obesity Animal
• Rеtаtrutіdе, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Human RCT
• Unleashing the power of rеtаtrutіdе: a possible triumph over obesity and its comorbidities Animal
• Triple-hormone-receptor agonist rеtаtrutіdе for obesity Human RCT
  

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.